Wolverine Stack (BPC-157 + TB-500): What the Research Actually Shows
The “Wolverine Stack” combines two research peptides promoted online for accelerated healing and recovery. This page reviews the preclinical evidence, the significant limitations of human data, and the current legal status.
Updated: March 2026
What Is the Wolverine Stack?
The “Wolverine Stack” is a popular term in online bodybuilding and biohacking communities referring to the combination of two synthetic peptides: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). The name is derived from the Marvel character known for rapid healing.
Proponents claim the combination produces synergistic effects on tissue repair, tendon and ligament healing, and recovery from injury. However, these claims are based primarily on extrapolation from separate preclinical studies, not on research into the combination itself.
BPC-157
- Synthetic peptide derived from a protein found in gastric juice
- 15 amino acids in length
- Studied primarily in rodent models of wound healing, tendon repair, and gut inflammation
- Also called “Body Protection Compound”
TB-500
- Synthetic fragment of Thymosin Beta-4 (TB4), a naturally occurring protein
- 43 amino acids in length
- Studied in animal models for wound healing and angiogenesis
- Not identical to the naturally occurring full-length protein
Proposed Mechanism of Action
The following mechanisms are proposed based on preclinical research. They have not been confirmed in human clinical trials.
BPC-157: Proposed Mechanisms (Preclinical)
- ›Upregulation of growth hormone receptor expression in tendon fibroblasts (rat models)
- ›Promotion of angiogenesis (new blood vessel formation) around injury sites
- ›Interaction with the NO-system (nitric oxide pathway) modulating vascular tone
- ›Cytoprotective effects in gut epithelium studied in colitis models
- ›Anti-inflammatory effects in rodent acute injury models
TB-500: Proposed Mechanisms (Preclinical)
- ›Binding to G-actin to promote cell migration (studied in vitro)
- ›Upregulation of metalloproteinases involved in tissue remodeling
- ›Promotion of angiogenesis in wound healing animal models
- ›Potential anti-inflammatory effects studied in corneal wound models
Evidence Level
Preclinical evidence only. Predominantly rodent studies. Mechanism plausible but unvalidated in controlled human trials.
Preclinical evidence only. Animal and in vitro data. No randomized controlled human trials published as of 2026.
Level C Definition: Evidence consists primarily of animal studies, in vitro data, or anecdotal case reports. Mechanism plausible but not validated by controlled human clinical trials. Cannot make reliable predictions about human efficacy or safety from Level C data alone.
Human Evidence (Severely Limited)
As of 2026, only approximately 3 human studies involving BPC-157 have been published. No published randomized controlled trials exist for TB-500 in humans.
The human data on BPC-157 consists of small, early-phase studies with significant methodological limitations. None have been large Phase 3 trials required for FDA approval or definitive efficacy claims.
Most claims about BPC-157 and TB-500 in online communities are based on extrapolating from rodent experiments to human physiology — a practice that has historically had a very high failure rate in drug development. Many compounds that appear highly effective in rodent models fail or cause harm in human trials.
The absence of human clinical trial data means there is no validated information on effective dosing ranges, optimal administration routes, long-term safety, or whether the proposed mechanisms translate to meaningful clinical benefit in humans.
Combination Evidence: None
No published studies — human or animal — have investigated the BPC-157 + TB-500 combination as of 2026.
The “synergy” claim is entirely theoretical. There is no published pharmacokinetic data on how these peptides interact when co-administered, whether competitive or complementary effects occur, or whether the combination carries additive safety risks. Using two insufficiently characterized research compounds together compounds the unknowns, not just the theoretical benefits.
FDA & Legal Status
FDA Category 2: Prohibited from Compounding (United States)
The FDA placed both BPC-157 and TB-500 on the Category 2 Bulk Drug Substances list (503A and 503B), meaning compounding pharmacies in the United States are prohibited from including these substances in medications. The FDA's stated reason: these substances raise significant safety concerns because adequate clinical investigation has not been conducted to determine if they are safe for use in compounded drug products.
Products sold as “research chemicals” or “for research use only” online are not subject to pharmaceutical manufacturing standards (GMP), purity verification, or dosing accuracy requirements.
Safety Concerns
In the absence of human clinical trial data, the complete safety profile of either peptide — and certainly the combination — is unknown. Known and theoretical concerns include:
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.